Clinical Trial NU MD11C03
- BTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
- Principal Investigator
- Jeffrey Raizer
- Status: COMPLETED
- Study Type: Supportive Care, Treatment
- Protocol No:.NU MD11C03
- This is a randomized double-blind study is to test if the drug Lacosamide, an antiepileptic (anti-seizure)medication,can prevent seizures in patients who have had surgery for a brain cancer called malignant glioma.
- This study is for patients who have had surgery for a brain cancer called malignant glioma. To date there have not been any definitive studies to determine the potential benefit of using anti-seizure medication to prevent seizures in at risk patients who have not yet had a seizure. Brain cancer patients who have undergone surgery for are at risk for seizures. This double-blind placebo study will assess the effectiveness of using Lacosamide, an FDA approved and commercially available anti-seizure drug, as a preventive medication to reduce the risk of seizures.
Some of the eligibility criteria include:
- Patients must have diagnosis of high-grade glioma.
- Patients must be 18 years of age or older.
- Patients must not have a history of any type of seizure for at least 10 years prior to registration.
- Description of Treatment
- Participants in this study will take the study drug every day for up to a year, unless the doctor asks the participant to stop taking the drug earlier for safety concerns.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
- A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
last updated: 01-Sep-15 05:16 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.